ERASCA INC (ERAS)
NASDAQ • Healthcare
Last close at August 10, 2026 at 20:00 UTC
Fundamentals Charts
About ERASCA INC
Erasca, Inc. is a NASDAQ-listed biotechnology company developing cancer therapies aimed at tumors driven by the RAS/MAPK pathway. The company operates as an early-stage drug developer in the healthcare sector and has built its business around a pipeline of candidates for difficult-to-treat malignancies.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
ERASCA INC's Technical Indicators Summary
ERAS registers balanced signals with price above major longer‑term averages but short‑term indicators subdued. RSI hovers around neutral and MACD is modestly positive while momentum is slightly negative, and ADX below 20 implies no dominant trend. Volatility is elevated relative to price, and on‑balance volume is negative, which tempers the constructive moving‑average alignment; the classic pivot is near the current level. Technical takeaway: Neutral—longer‑term moving averages are supportive but recent momentum and volume are inconclusive.
| Indicator | Value |
|---|---|
RSI (14) | 50.41 |
Stochastic %K (14, 3, 3) | 41.20 |
CCI (20) | -70.00 |
WPR (14) | -63.89 |
Momentum (10) | -0.75 |
MFI | 38.59 |
MACD Level (12, 26) | 0.29 |
Bollinger Bands | $17.23 - $20.41 |
ATR (14) | $1.12 (6.18%) |
ADX (14) | 18.46 |
OBV | 145,937,285 |
Classic Pivot Point | $18.35 |
Fibonacci Pivot Point | $18.35 |
Simple Moving Averages | $11.38 - $18.82(5 indicators) |
Exponential Moving Averages | $11.36 - $18.38(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
ERAS gave back a sliver of ground in the last session, finishing at 18.12 after a small -1.58% decline. ERAS appoints ex-Genentech executive Michael Fuchs as President of R&D, boosting its leadership.
Trading Volume
Below 10d avg (3.4M)
2.4M
vs S&P 500 Today
Underperforming Market
-1.52%
52-Week Position
Upper range
73.2%
Updated: August 11, 2026 at 12:46 UTC
Quote Summary
ERAS Headlines
Biotech & AI Fuel Big Stock Moves
January 20, 2026